Study the prevalence of rifampicin resistance among pulmonary tuberculosis patients by genexpert assay from a tertiary care hospital of North India

Background: Rifampicin (RIF) resistance (RR) tuberculosis (TB) has posed a great challenge to TB control programs globally. Evidence of RIF-RR can help as a surrogate marker to find out multidrug-resistance cases. The study aimed to determine the prevalence of RIF-RR in pulmonary TB (PTB) patients...

Full description

Bibliographic Details
Main Authors: Jitendra Chandra Devrari, Madhu Chauhan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:International Journal of Mycobacteriology
Subjects:
Online Access:http://www.ijmyco.org/article.asp?issn=2212-5531;year=2023;volume=12;issue=2;spage=175;epage=178;aulast=Devrari
_version_ 1797774258458329088
author Jitendra Chandra Devrari
Madhu Chauhan
author_facet Jitendra Chandra Devrari
Madhu Chauhan
author_sort Jitendra Chandra Devrari
collection DOAJ
description Background: Rifampicin (RIF) resistance (RR) tuberculosis (TB) has posed a great challenge to TB control programs globally. Evidence of RIF-RR can help as a surrogate marker to find out multidrug-resistance cases. The study aimed to determine the prevalence of RIF-RR in pulmonary TB (PTB) patients over the 4 years at Dr. RPGMC, Tanda, from the year 2018 to 2021. Methods: This was a retrospective study conducted at Dr. RPGMC, Tanda at Kangra, where we checked (from January 2018 to December 2021) clinically suspected PTB patients, whose samples were sent to the laboratory for GeneXpert assay to identify Mycobacterium TB/RIF (MTB/RIF) testing. Results: Of the total 11,774 clinically suspected PTB specimens were collected, and identified by GeneXpert MTB/RIF assay, in which 2358 samples were MTB positive and 9416 were MTB negative. Among 2358 MTB-positive samples, 2240 (95%) samples were RIF sensitive, in which 1553 (65.9%) were males and 687 (29.1%) were females, 76 (3.2%) samples were RIF-RR, in which 51 (2.2%) were males and 25 (1%) were females, and 42 (1.8%) samples were RIF indeterminate, in which 25 (1%) were males and 17 (0.8%) were females. Conclusion: The rate of RIF-RR was found 3.2% of total samples which was more in males. The overall positivity rate was 20%, and the rate of positivity decreased from 32% to 14% over the 4 years in sputum samples. Hence, the GeneXpert assay was found to be very important tool to detect RIF-RR among suspected PTB patients.
first_indexed 2024-03-12T22:17:26Z
format Article
id doaj.art-fe5c4bdb08e441a8b7f17a0951649334
institution Directory Open Access Journal
issn 2212-5531
2212-554X
language English
last_indexed 2024-03-12T22:17:26Z
publishDate 2023-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series International Journal of Mycobacteriology
spelling doaj.art-fe5c4bdb08e441a8b7f17a09516493342023-07-23T11:14:42ZengWolters Kluwer Medknow PublicationsInternational Journal of Mycobacteriology2212-55312212-554X2023-01-0112217517810.4103/ijmy.ijmy_219_22Study the prevalence of rifampicin resistance among pulmonary tuberculosis patients by genexpert assay from a tertiary care hospital of North IndiaJitendra Chandra DevrariMadhu ChauhanBackground: Rifampicin (RIF) resistance (RR) tuberculosis (TB) has posed a great challenge to TB control programs globally. Evidence of RIF-RR can help as a surrogate marker to find out multidrug-resistance cases. The study aimed to determine the prevalence of RIF-RR in pulmonary TB (PTB) patients over the 4 years at Dr. RPGMC, Tanda, from the year 2018 to 2021. Methods: This was a retrospective study conducted at Dr. RPGMC, Tanda at Kangra, where we checked (from January 2018 to December 2021) clinically suspected PTB patients, whose samples were sent to the laboratory for GeneXpert assay to identify Mycobacterium TB/RIF (MTB/RIF) testing. Results: Of the total 11,774 clinically suspected PTB specimens were collected, and identified by GeneXpert MTB/RIF assay, in which 2358 samples were MTB positive and 9416 were MTB negative. Among 2358 MTB-positive samples, 2240 (95%) samples were RIF sensitive, in which 1553 (65.9%) were males and 687 (29.1%) were females, 76 (3.2%) samples were RIF-RR, in which 51 (2.2%) were males and 25 (1%) were females, and 42 (1.8%) samples were RIF indeterminate, in which 25 (1%) were males and 17 (0.8%) were females. Conclusion: The rate of RIF-RR was found 3.2% of total samples which was more in males. The overall positivity rate was 20%, and the rate of positivity decreased from 32% to 14% over the 4 years in sputum samples. Hence, the GeneXpert assay was found to be very important tool to detect RIF-RR among suspected PTB patients.http://www.ijmyco.org/article.asp?issn=2212-5531;year=2023;volume=12;issue=2;spage=175;epage=178;aulast=Devrarigenexpert assaymycobacterium tuberculosispulmonary tuberculosisrifampicin resistance
spellingShingle Jitendra Chandra Devrari
Madhu Chauhan
Study the prevalence of rifampicin resistance among pulmonary tuberculosis patients by genexpert assay from a tertiary care hospital of North India
International Journal of Mycobacteriology
genexpert assay
mycobacterium tuberculosis
pulmonary tuberculosis
rifampicin resistance
title Study the prevalence of rifampicin resistance among pulmonary tuberculosis patients by genexpert assay from a tertiary care hospital of North India
title_full Study the prevalence of rifampicin resistance among pulmonary tuberculosis patients by genexpert assay from a tertiary care hospital of North India
title_fullStr Study the prevalence of rifampicin resistance among pulmonary tuberculosis patients by genexpert assay from a tertiary care hospital of North India
title_full_unstemmed Study the prevalence of rifampicin resistance among pulmonary tuberculosis patients by genexpert assay from a tertiary care hospital of North India
title_short Study the prevalence of rifampicin resistance among pulmonary tuberculosis patients by genexpert assay from a tertiary care hospital of North India
title_sort study the prevalence of rifampicin resistance among pulmonary tuberculosis patients by genexpert assay from a tertiary care hospital of north india
topic genexpert assay
mycobacterium tuberculosis
pulmonary tuberculosis
rifampicin resistance
url http://www.ijmyco.org/article.asp?issn=2212-5531;year=2023;volume=12;issue=2;spage=175;epage=178;aulast=Devrari
work_keys_str_mv AT jitendrachandradevrari studytheprevalenceofrifampicinresistanceamongpulmonarytuberculosispatientsbygenexpertassayfromatertiarycarehospitalofnorthindia
AT madhuchauhan studytheprevalenceofrifampicinresistanceamongpulmonarytuberculosispatientsbygenexpertassayfromatertiarycarehospitalofnorthindia